Cited 0 times in Scipus Cited Count

The comparison of Carfilzomib, and dexamethasone versus pomalidomide-based combination chemotherapy after a 2nd-line therapy in relapsed and refractory multiple myeloma patients

DC Field Value Language
dc.contributor.authorLee, JH-
dc.contributor.authorKim, SH-
dc.contributor.authorLee, YJ-
dc.contributor.authorMin, CK-
dc.contributor.authorPark, SS-
dc.contributor.authorKim, K-
dc.contributor.authorShin, DY-
dc.contributor.authorPark, JS-
dc.contributor.authorShin, HJ-
dc.contributor.authorLee, HS-
dc.contributor.authorJo, JC-
dc.contributor.authorLee, WS-
dc.contributor.authorYhim, HY-
dc.contributor.authorKwak, JY-
dc.contributor.authorLee, Jy-
dc.contributor.authorByun, JM-
dc.contributor.authorChoi, YS-
dc.date.accessioned2020-11-17T05:29:36Z-
dc.date.available2020-11-17T05:29:36Z-
dc.date.issued2019-
dc.identifier.issn2152-2650-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/19065-
dc.language.isoen-
dc.titleThe comparison of Carfilzomib, and dexamethasone versus pomalidomide-based combination chemotherapy after a 2nd-line therapy in relapsed and refractory multiple myeloma patients-
dc.typeArticle-
dc.subject.keywordcarfilzomib-
dc.subject.keywordPomalidomide-
dc.subject.keywordrelapsed/refractory multiple myeloma-
dc.contributor.affiliatedAuthor박, 준성-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.clml.2019.09.437-
dc.citation.titleClinical lymphoma, myeloma & leukemia-
dc.citation.volume19-
dc.citation.number10-
dc.citation.date2019-
dc.citation.startPagee264-
dc.citation.endPagee265-
dc.identifier.bibliographicCitationClinical lymphoma, myeloma & leukemia, 19(10). : e264-e265, 2019-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn2152-2669-
dc.relation.journalidJ021522650-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse